Abstract:Ethnopharmacological relevance Astragalus mongholicus (AM) is a Qi-tonifying and immune-regulating herb widely used in traditional Chinese medicine (TCM), which is increasingly regarded as a profound complementary medication in the treatment of fibrosis disease. Astragaloside (AS), astragaloside flavonoids (AF) and astragaloside polysaccharides (APS) are the main active ingredients of Astragalus Mongholicus (AM) that have a significant therapeutic effect on liver fibrosis. Aim of the study This systematic review and meta-analysis aims to evaluate the effects and possible mechanisms of the main active ingredients of AM including astragaloside (AS), astragalus flavone (AF) and astragalus polysaccharide (APS) in animal models of liver fibrosis. Materials and methods We systematically searched ten databases PubMed, Web of Science, Embase, Scopus, CINAHL, ProQuest database, China National Knowledge Internet (CNKI), VIP Information Chinese Periodical Service Platform (VIP), WangFang database and China Biology Medicine Disc (CBM) to identify relevant animal studies from inception to November 2022. The SYRCLE's risk of bias tool was used to assess the methodological quality. The statistical analysis was performed using RevMan 5.4 software. Results Twenty-three studies involving 482 animals were included. Studies quality scores ranged from 4 to 5. Alanine aminotransferase (ALT) (SMD, −3.87; 95% CI, −5.09 to −2.65; P < 0.00001) aminotransferase (AST) (SMD, −4.43; 95% CI, −5.77 to −3.08; P < 0.00001), hydroxyproline (HYP) (SMD, −2.94; 95% CI, −3.83 to −2.05; P < 0.00001) and transforming growth factor-β1 (TGF-β1) (SMD, −2.82; 95% CI, −3.57 to −2.06; P < 0.00001) were the main outcome measures to be analyzed. The meta-analysis revealed that the main active ingredients of AM lowered the levels of known risk factors including liver index (SMD, −1.25; 95% CI, −1.63 to −0.87; P < 0.00001), degree of liver fibrosis (SMD, −1.93; 95% CI, −2.57 to −1.28; P < 0.00001), collagen α type I (Col)-1 (SMD, −3.71; 95% CI, −5.63 to −1.79; P = 0.0001), hyaluronic acid (HA) (SMD, −2.65; 95% CI, −3.69 to −1.61; P < 0.00001), laminin (LN) (SMD, −2.06; 95% CI, −2.51 to −1.61; P < 0.00001), type IV collagen (CIV) (SMD, −3.04; 95% CI, −4.34 to −1.74; P < 0.00001), procollagen typeIII (PCIII) (SMD, −2.60; 95% CI, −3.15 to −2.05; P < 0.00001), albumin (ALB) (SMD, −1.19; 95% CI, −1.63 to −0.75; P < 0.00001), total bilirubin (TBiL) (SMD, −3.63; 95% CI, −5.39 to −1.88; P < 0.0001), α-smooth muscle actin (α-SMA) (SMD, −5.27; 95% CI, −6.94 to −3.61; P < 0.00001) and Smad3 (SMD, −4.11; 95% CI, −7.17 to −1.05; P = 0.009) level. Conclusion Our meta-analysis demonstrates the effective role of the main active ingredients of AM in preclinical studies of liver fibrosis. The underlying mechanisms may be related to attenuation of oxidative stress, modulation of inflammatory response and inhibition of collagen production. However, due to the significant heterogeneity and poor quality of included studies, positive findings should be treated cautiously. Registration PROSPERO ID CRD42023382282

Astragali Radix Contributes to the Inhibition of Liver Fibrosis via High-Mobility Group Box 1-Mediated Inflammatory Signaling Pathway

Metabolomics Combined with Network Pharmacology Exploration Reveals the Modulatory Properties of Astragali Radix Extract in the Treatment of Liver Fibrosis

Integrating Network Pharmacology and Experimental Validation to Investigate the Effects and Mechanism of Astragalus Flavonoids Against Hepatic Fibrosis

Astragalus polysaccharide alleviates alcoholic-induced hepatic fibrosis by inhibiting polymerase I and transcript release factor and the TLR4/JNK/NF-κB/MyD88 pathway

Effect of Astragalus complanatus flavonoid on anti-liver fibrosis in rats

Astragalus and Paeoniae radix rubra extract inhibits liver fibrosis by modulating the transforming growth factor-β/Smad pathway in rats

Efficacy and potential mechanisms of the main active ingredients of astragalus mongholicus in animal models of liver fibrosis: A systematic review and meta-analysis

The Anti-inflammatory Effects of Isoflavonoids from Radix Astragali in Hepatoprotective Potential against LPS/D-gal-induced Acute Liver Injury

[Study on the Inhibitive Effect of Astragalus Injection Solution on Hepatic Fibrosis in Rats].

Anti-Atherosclerotic Function of Astragali Radix Extract: Downregulation of Adhesion Molecules in Vitro and in Vivo

Arctigenin induces activated HSCs quiescence via AMPK-PPARγ pathway to ameliorate liver fibrosis in mice

[Effects of Anluohuaxianwan on Transforming Growth Factor-Β1 and Related Signaling Pathways in Rats with Carbon Tetrachloride-Induced Liver Fibrosis].

[Astragalus Polysaccharides and Astragalosides Regulate Cytokine Secretion in LX-2 Cell Line].

The effect of Astragalus injection on CCl4 -ethanol- induced rat hepatic fibrosis

Astragalus saponins and its main constituents ameliorate ductular reaction and liver fibrosis in a mouse model of DDC-induced cholestatic liver disease

Ginsenoside Rg3 promotes regression from hepatic fibrosis through reducing inflammation-mediated autophagy signaling pathway

Amygdalin Ameliorates Liver Fibrosis Through Inhibiting Activation of TGF-β/Smad Signaling

Antrodia camphorata-Derived Antrodin C Inhibits Liver Fibrosis by Blocking TGF-Beta and PDGF Signaling Pathways

Agastache rugosa alleviates the multi-hit effect on hepatic lipid metabolism, inflammation and oxidative stress during nonalcoholic fatty liver disease

Active substances and molecular mechanisms of Astragali Radix and Angelicae Sinensis Radix against idiopathic pulmonary fibrosis effects by network pharmacology and in vitro experiments

Network-driven Targeted Analysis Reveals That Astragali Radix Alleviates Doxorubicin-Induced Cardiotoxicity by Maintaining Fatty Acid Homeostasis.